Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Autor: Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing

Publikováno v: Frontiers in Pharmacology, Vol 13 (2022)

Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood g

Externí odkaz: https://doaj.org/article/566f5b4cc054458fb0059e50badd6cf6

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Autor: Verusca Lecchi, Pamela Surtees, Jessie A. Hermann, Marina Noutsou, Lidmila Francová, Francesca Lo Bue, Silvia Prandini, Annika Durban, Heidrun Wölk, Suzy van Steenderen, Gemma Currie, Rüdiger Göke, Ivan Rychlik, Daniela Cugini, Annette Busmann, Ulrike Wittkop, Svitlana Yakymchuk, John R. Petrie, Slavica S. Stratrova, Stanley M H Yeung, Julia Raad, Antonio Cannata, Ninna Hahn Tougaard, Robbie Wilson, Barbara Neuhaus, Joachim Beige, Olivera Stojceva-Taneva, Harald Mischak, Tine W. Hansen, Giulia Gherardi, Caroline Boukens-de Graaf, Renata Amanaki, Francesco Nones, Anneke K. De Bruin, Aneliya Parvanova, Elizabeth Douglas, Carolina Aparicio, Gerjan Navis, Tereza Havrdova, Alberto Ortiz, Maria Dolores Sanchez-Niño, Simone Theilade, Ferrina Clerc-de Jong, Signe Abitz Winther, Adrian M. Ramos, Regina Ax-Smolarski, Ingo Dimos, Christina M. Gant, Peter Girman, Friedrich W. Petry, Peter Rossing, Bruno Lapauw, Katarina Adamova, Rikke J. Stefansen, Michael Prigge, Mie K. Eickhoff, Petra Zürbig, Viktor Rotbain Curovic, Davide Villa, Goce Spasovski, Marian Nannings, Adriaan Kooy, Joanne Flynn, Therese Frost Lerche, Veit Zieglschmid, Flavio Gaspari, Gjulsen Selim, Marijn M. Speeckaert, Jens C. Laursen, Elsie de Man, Signe Rosenlund, Christian Delles, Giel Nijpels, Katriona Brooksbank, Alessandro Villa, Ilian Iliev, Morten Lindhardt, Maria A. Campbell, Lone Jelstrup, Gozewijn D. Laverman, Matias Trillini, Ulrike Schmidt, Kristin Kreutzmann, Silke Zimmermann, Ceyda Kilic, Tina R. Juhl, Silvia Ferrari, Nadia Stucchi, Beatriz Fernandez-Fernandez, Christian Stevns Hansen, Femke Rutters, Brenda Wierbos, Sabien Inion, Maria Lajer, Justyna Siwy, Jannet Entius, Sascha Pilemann-Lyberg, Lene Aabo, Heiko von der Leyen, Elina Eldeik, Tatjana Gjorgovski, Marie Frimodt-Møller, Isabelle Dewettinck, Maja L.D. Halkjær, Joline W.J. Beulens, Šárka Albrechtová, Stephan J. L. Bakker, Hiddo J.L. Heerspink, Brit Rädisch, Clotilde Vázquez, Ilse J. M. Hagedoorn, Dorthe Riis, Bernt Johan von Scholten, Andreas L. Birkenfeld, Kelly Rokegem, Ana Belen Sanz, Frederik Persson, Eva Bollweber, Anika Hävemeier, Frank Huvers, Petra Schutten-Westerneng, Piero Ruggenenti, Sharon Kean, Maria Á. Gonzalo, Anne G. Lundgaard, Marco Schiemann, Emilie H. Zobel, Nete Tofte, Joe Galloway, Daniela Melacini, Jinny Sanchez-Rodriguez

Publikováno v: Lancet Diabetes & Endocrinology, 8(4), 301-312. ELSEVIER SCIENCE INC
Tofte, N, Lindhardt, M, Adamova, K, Bakker, S J L, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Heerspink, H J L, Kooy, A, Laverman, G D, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, J R, Ruggenenti, P L, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H, Rossing, P, PRIORITY investigators & Nijpels, MGAAM 2020, ' Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY) : a prospective observational study and embedded randomised placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 8, no. 4, pp. 301-312 . https://doi.org/10.1016/S2213-8587(20)30026-7
Ann Transl Med
The Lancet Diabetes and Endocrinology, 8(4), 301-312. Elsevier BV
Lancet Diabet. Endocrinol. 8, 301-312 (2020)

Background: \ud Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c330f7cf6c46dc4a204c768eaea4bed
https://eprints.gla.ac.uk/212534/13/212534.pdf

526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

Autor: Peter Rossing, Marie Frimodt-Møller, Mie K. Eickhoff, Harald Mischak, Frederik Persson

Publikováno v: Diabetes. 68

Objective: Evaluating effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the urinary CKD273 proteomic score in patients with type 2 diabetes (T2D) and albuminuria. Methods: A double-blinded, randomized, placebo-controlled, crosso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da7161b35f3809c42249dff6d3704472
https://doi.org/10.2337/db19-526-p

SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY

Autor: Niklas Rye Jørgensen, Frederik Persson, Marie Frimodt-Møller, Peter Rossing, Mie K. Eickhoff

Publikováno v: Nephrology Dialysis Transplantation. 33:i488-i488

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42e55213f47ca50bb29d0891e4bd297f
https://doi.org/10.1093/ndt/gfy104.sp417